share_log

Barclays Maintains Overweight on Ligand Pharmaceuticals, Lowers Price Target to $110

Benzinga ·  Jul 25, 2023 06:59

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and lowers the price target from $120 to $110.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment